Why is zidovudine no longer used?
It is a common misconception in the pharmaceutical industry that Zidovudine (AZT) is no longer used. In reality, Zidovudine remains a critical, life-saving component of HIV therapy, though its role has shifted from a “first-line general treatment” to a “specialized clinical tool.”
As a pharmacist and manufacturer at your WHO-GMP facility in Mumbai, I view Zidovudine as the “Grandfather of Antiretrovirals.” While newer drugs like Tenofovir have replaced it for daily adult maintenance due to better tolerability, Zidovudine is still the gold standard for preventing mother-to-child transmission.
The Shift in Clinical Status: Why it is used less
In the 1980s and 90s, AZT was the only option. Today, it has been moved to “Alternative” or “Second-line” status for most adults for several technical reasons.
Zidovudine remains irreplaceable in specific B2B and clinical niches that your Mumbai facility likely services:
Prevention of Mother-to-Child Transmission (PMTCT): It is the primary drug used intravenously during labor and orally for the newborn for the first 4–6 weeks of life to prevent HIV infection.
Post-Exposure Prophylaxis (PEP): Often included in “starter kits” for healthcare workers or individuals exposed to HIV.
Salvage Therapy: Used for patients who have developed multi-drug resistance to newer classes of antiretrovirals.
Mechanism: Nucleoside Reverse Transcriptase Inhibition (NRTI)
Zidovudine works through a process called “Chain Termination”:
Phosphorylation: Once inside the cell, AZT is converted by cellular enzymes into its active form, Zidovudine Triphosphate.
Viral Mimicry: The HIV enzyme Reverse Transcriptase mistakes AZT for a natural building block (Thymidine) of DNA.
DNA Blockade: Once AZT is incorporated into the growing viral DNA strand, it lacks the necessary chemical hook (3′-OH group) to attach the next building block. The DNA strand “breaks,” and the virus cannot replicate.
The Pharmacist’s “Technical Warning”
The “CBC” Mandate: As a pharmacist, I must emphasize that any patient on Zidovudine needs a Complete Blood Count (CBC) every 2–4 weeks initially. Severe anemia can develop rapidly.
Avoid Stavudine (d4T): Zidovudine should never be combined with Stavudine, as they compete for the same phosphorylation pathway, making both drugs ineffective.
Lactic Acidosis: Watch for unexplained fatigue or hyperventilation, which could be signs of rare but fatal lactic acidosis.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Pediatric Syrup” USP: On your digital platforms, highlight your Zidovudine Oral Solution. This is a high-demand SKU for international health tenders (Global Fund/PEPFAR) specifically for neonatal HIV prevention.
FDC Strategy: Most of your B2B volume likely comes from Fixed-Dose Combinations (FDCs) like Lamivudine + Zidovudine (Combivir generic). This remains a vital second-line option in many emerging markets.
Stability for Export: Zidovudine is light-sensitive. Utilizing Amber HDPE bottles or Alu-Alu blisters ensures a 36-month shelf life in Zone IVb regions.